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The contemporary physician and 
his patient are riding the crest of 
the most dramatic expansion of 
medical capability in history. But 
the rapid proliferation of medical 
knowledge has not been entirely 
benign. Although our reverses have 
been minor in contrast to our ad-
vances, negative effects cannot be 
ignored. My discussion involves 
one aspect of this problem-the 
emergence of what I have called 
"Diseases of Medical Progress" 
(Moser, 1964) . 
Pertinent to the evolution of 
medical capability has been the 
improvement in quantity and qual-
ity of drugs. In the early days new 
drugs came in a trickle, and there 
was time for the physician to be-
come familiar with their virtues 
and idiosyncrasies. Soon the trickle 
became a stream, and there was 
less time for study and reflection. 
The stream has now become a tor-
rent; it is impossible for the physi-
cian to keep pace. His little black 
bag runneth over. 
It has been said that drug-
induced adverse effects are the 
price we have to pay for more 
effective medicaments (Zbinden, 
1964). There can be no quarrel 
with this statement; it is the high 
price we are haggling about. The 
thalidomide disaster indicated how 
expensive it can be. 
The deluge of new drugs has 
produced widespread discontent 
with empiricism in therapeutics. 
The modern practitioner demands 
drugs with proper credentials. This 
has precipitated a virtual renais-
sance in drug investigation, and 
thus we have come to learn more 
of the wonders and hazards of con-
temporary therapeutic agents. 
The demands of the clinician to 
know more about drugs are being 
met by increasing capability in the 
laboratory. New insight and ap-
preciation of the complexities of 
drug effects have come from sev-
eral diverse avenues of investiga-
tion. The wedding of percutaneous 
biopsy and electron microscopy 
has resulted in dramatic revela-
tions; the mysteries of intracellu-
lar morphology and physiology in 
the living organism have begun to 
yield. Often, we are able to ob-
serve the specific site of drug ac-
tion within the cell. 
In other areas techniques con-
tinue to be perfected for assay of 
blood and tissue levels of drugs, 
intermediate products and enzymes. 
The problems of adverse drug ef-
fects are many. Reduced to sim-
plest elements, when Drug "A" is 
introduced into the body, ulti-
mately it or its intermediate pro-
ducts will be carried in blood and 
body fluids to all cells of the or-
ganism. The effects of Drug "A" 
become clinically perceptible only 
when the function of certain organs 
is modified, either beneficially or 
detrimentally, to the point of pro-
ducing perceptible changes, and it 
is by these phenomena that we 
learn to characterize the nature of 
Drug "A." As we focus attention 
upon the response of a specific 
organ (or organs) to th is drug, we 
are inclined to forget that Drug 
"A" is also in contact with other 
tissues of the organism. Effects in 
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these areas are not immediately de-
tectible, but may become manifest 
clinically at a later date. Such long-
range effects may never be corre-
lated with the antecedent adminis-
tration of Drug "A." 
Only painstaking retrospective 
analysis of many cases will uncover 
a suspected denominator. Then we 
must follow with a meticulously 
controlled prospective study which 
will involve provocative testing in 
acceptable laboratory animals be-
fore we can prove that indeed it 
was Drug "A" that caused the 
chronic disease. The problems of 
extrapolating this data to humans 
are evident. This is a shadow world 
of pathophysiology where relation 
of cause to effect is at best difficult 
to assess. I need only cite the still 
raging controversy over phenace-
tin and renal disease to demon-
strate the difficulty. There are other 
problems. 
What is known of the role 
played by drugs in predisposing the 
organism to attack by micro-organ-
isms or degenerative disease? An 
example is the effect of long-term 
corticosteroids in predisposing the 
leukemia or lymphoma patient to 
systemic fungus infections. 
We are hearing more about the 
so-called "opportunistic organisms" 
- perhaps a semantically poor eu-
phemism. But it is appropriate to 
our thesis to mention Candida al-
bicans (Seelig, 1966). This is a 
saprophyte of limited pathogenicity 
under normal circumstances, but 
may emerge as a systemic infection 
and seed into many organs during 
or following broad spectrum anti-
biotic administration, with or with-
out concomitant corticosteroid or 
immunosuppressive therapy. This 
phenomenon has been related to 
suppression of susceptible enteric 
flora with disruption of the normal 
ecologic balance permitting the un-
suppressed saprophytes to prolifer-
ate and escape their enteric confines. 
The devastating influence of pro-
longed corticosteroid therapy upon 
the elderly patient immobilized by 
cardiovascular disease or arthritis, 
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in whom accelerated demineraliza-
tion occurs through corticosteroid 
anti-anabolic effect, is an example 
of exaggeration of degenerative dis-
ease caused by a drug. We start 
with one disease and our treatment 
for it produces another disease. 
Let us modify the question again. 
What is known of the effects of 
drugs upon a previously diseased 
organ, with limited capability to 
metabolize or detoxify or otherwise 
cope with a drug given to treat 
another illness? I have mentioned 
the phenacetin controversy. The 
discussion here revolves around the 
status of analgesic compounds in 
the provocation of interstitial pye.-
lonephritis in a normal kidney. But 
what effect do phenacetin, aspirin, 
or the combination have upon a 
sick kidney, already poorly dis-
posed to resist assault from either 
micro-organism or nephrotoxic 
drug? 
Consider the patient with sub-
clinical hepatic disease, e.g., a mild 
cirrhosis, who is given chlorproma-
zine or phenylbutazone, drugs 
known to be occasionally toxic to 
the liver. One could cite multiple 
examples wherein an organ with 
marginal function may be further 
insulted by a drug administered, 
most innocently and with proper 
indication, to treat another ailing 
system. 
Pharmacogenetics and Enzyme 
Induction 
Perhaps the most fascinating 
corollary to these observations is 
the identification of a relationship 
between enzyme systems and drug 
effects. Vogel (1959) introduced 
the term "pharmacogenetics" into 
clinical medicine. This was defined 
as "the study of genetically de-
termined variations that are re-
vealed solely by the effects of 
drugs." The genetic variation re-
sults in the absence or insufficiency 
of certain enzyme systems. This 
mechanism has already been cited 
as one major explanation of the ex-
traordinary human variability in 
response to conventional doses of 
conventional drugs (Evans, 1963). 
The historical and classical ex-
ample of a pharmacogenetic dis-
ease is the hemolytic anemia suf-
fered by some members of certain 
ethnic groups, specifically, Mediter-
ranean basin dwellers and Negroes 
(Berry, 1965; Beutler et al., 1955). 
Brisk hemolysis may follow ex-
posure to many common therapeu-
tic agents (among these are the 
4-aminoquinolines, certain sulfona-
mides, acetylsalicylic acid, the ni-
t r of ur ant o ins, sulfones, para-
amino-salycylic acid, phenacetin 
acetanilid, probanthine and the 
water soluble analogues of vitamin 
K). Even the Fava bean apparently 
provokes hemolytic anemia on the 
same basis. 
The cause is a genetically trans-
mitted defect that results in de-
ficiency of the intra-erythrocytic 
enzyme, glucose-6-phosphate dehy-
drogenase. Such patients are nor-
mal clinically; they have no mor-
phologic or physiologic abnormality 
of their red cells, until one of the 
provocative drugs is given. Then 
brisk hemolysis occurs. Deficiency 
of glucose-6-PD has been cited as 
one cause of neonatal jaundice. It 
is somewhat of a problem in the 
chloroquine primaquine anti-malar-
ial prophylaxis program in South-
east Asia (personal communica-
tion, Col. Marshal McCabe). 
Other red cell enzyme deficien-
cies of greater subtlety have begun 
to emerge; these include aldolase, 
catalase, glutathione, glutathione 
reductase, pyruvate kinase, triose 
phosphatase and isomerases. 
In addition, kernicterus of the 
newborn is related to immaturity 
of the neonatal liver. This organ is 
deficient in glucoronosyl transfer-
ase and, therefore, unable to con-
jugate bilirubin. Administration of 
sulfisoxazole (Gantrisin) or vita-
min K analogues exaggerates this 
reaction. Novobiocin may provoke 
jaundice in the newborn and rarely 
in adults by direct inhibition of 
glucoronosyl transferase (Moser, 
1967, in press). 
Do these adults have a marginal 
deficiency of this enzyme which 
becomes evident only when they 
are challenged with novobiocin? Is 
it congenital, or is it acquired as 
the result of a preceding episode of 
hepatic disease? 
There are other equally fascin-
ating pharmacogenetic diseases. 
Hemoglobin Zurich (Frick, Hitzig, 
and Betke, 1962) is an example. If 
a certain Swiss family had not been 
given sulfonamide drugs, it is quite 
likely that this abnormal hemoglo-
bin disease would have continued 
to escape detection. A frank hemo-
lytic anemia developed after admin-
istration of sulfadimethoxine and 
sulfamethoxypyridizine (Kynex) to 
family members. A new hemoglo-
bin with electrophoretic mobility 
between A and S was identified; 
fingerprints of peptic digests re-
vealed three unusual peptides. 
Time permits only a brief glance 
at other equally fascinating pharm-
acogenetic disorders. 
( 1) Hemoglobin H disease : pa-
tients with this illness have hemo-
globin which is a tetramer of four 
beta chains. Their erythrocytes ap-
pear normal until they are given 
sulfisoxazole ; then a brisk hemoly-
tic anemia may develop. 
(2) Patients may be divided into 
phenotypes on the basis of their 
ability in inactive isoniazid (Por-
ter, 1964; Editorial, S. African 
Med. J., 1964). There is reason to 
suspect that isoniazid polyneuro-
pathy is more common in "slow in-
activators" than "rapid inactiva-
tors." Fortunately there 1s no 
difference in therapeutic respon-
siveness to isoniazid, and the de-
velopment of resistance by the 
tubercle bacillus to isoniazid is 
similar in the two phenotypes. 
(3) About 1 % to 2% of pa-
tients have a genetically determined 
deficiency of pseudocholinesterase 
(Hodgkin et al., 1965) ; This may 
be qualitative or quantitative. The 
malady will remain asymptomatic 
and undetected unless the patient 
is challenged with suxamethonium. 
Then the response is dramatic; a 
2 to 3 min period of apnea will 
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ensue. Pseudocholinesterase is re-
quired to metabolize suxametho-
nium. 
( 4) It is suspected that in-
creased susceptibility to dyskinesias 
subsequent to administration of 
phenothiazines such as chlorpro-
mazine, may have a genetic basis. 
And in view of the multitude 
of known enzyme systems, as well 
as those suspected but not as yet 
identified, one could predict that 
many reactions now classified as 
idiosyncratic or hypersensitive will 
soon be gathered into the fold of 
pharmacogenetic disorders or ac-
quired enzyme insufficiencies. 
A related phenomenon is drug-
induced inhibition of the metabolic 
breakdown or release of albumin 
binding with escape of free drug. 
This is epitomized by the potentia-
tion of coumarin drugs by sev-
eral rather common agents, such 
as phenyramidol (Carter, 1965) , 
acetyl salicylic acid, tetracycline, 
streptomycin, D-thyroxine, andro-
steneolone, phenylbutazone (Eisen, 
1964) and oxyphenbutazone (Fox, 
1964). 
Now there is a new dimension, 
quite antithetical to the concept of 
enzyme deficiencies unmasked or 
inhibition of metabolic breakdown 
caused by drugs. This is the· phe-
nomenon of "enzyme induction," 
in which the administration of one 
drug accelerates the metabolic 
breakdown of another. (Burns, et 
al., 1965; Conney and Burns, 1963; 
Fouts, 1963) . Clinical suspicion 
was aroused when it was discov-
ered that some patients receivil)g 
coumarin drugs required increased 
doses to maintain therapeutic anti-
coagulant levels while taking bar-
biturates. 
Residual Drug Effects 
Residual drug effects re.main an-
other enigmatic area. For example, 
reserpine continues to exert its 
influence jn certain patients for 
several weeks after it has been dis-
continued. It may cause unpredict-
able responses to general anesthe-
sia. Reserpine may obscure the 
phentolamine (Regitine) test for 
pheochromocytoma for several 
weeks after it has been stopped. 
The persisting and even progressive 
retinal damage induced by resid-
ual chloroquine has been the sub-
ject of much commentary. 
Elevated levels of protein bound 
iodine were found in the sera of 
women who had received iophe-
noxic acid (Teridax, a cholecysto-
graphic medium) six to seven years 
previously. Babies born several 
years after their mothers had in-
gested iophenoxic acid had ex-
tremely high levels of protein 
bound iodine (Goss and Dickhaus, 
1965). These agents may lie dor-
mant in fat depots for many years, 
apparently innocuous, but in cur-
ious contradiction to the usual tend-
ency of an organism to rid itself of 
foreign substances. What other 
drugs are "stored" for prolonged 
periods? Do they exert adverse ef-
fects? Questions come easily; an-
swers do not. 
An equally fascinating new as-
pect of drug mechanisms is revealed 
in the recently recognized phenom-
enon of transferable drug resist-
ance. This was first observed in 
Japan in 1959 during studies on 
Shigella which proved resistant to 
several anti-microbial agents. It is 
now recognized that Shil!ella and 
Salmonella are capable of genetic 
transm1ss10n of drug resistance 
(Smith, 1966). It has been sug-
gested that the widespread use of 
antibacterial drugs in agricultural 
feeds has contributed to this prob-
lem. To my knowledge genetically 
transferred resistance factors have 
been identified only in gram-nel!a-
tive micro-organisms and acid-fast 
bacilli. 
Now that we have seen some-
thing of the broad introductory 
area of drug-induced diseases, a 
logical question might be: What 
will be the ultimate effect of these 
new therapeutic endeavors? The an-
swer must lie somewhere in the in-





The evolution of man is a con-
tinuing source of wonderment to 
students of physiology. Through 
the centuries of painful metamor-
phosis, each challenge thrown at 
man by his environment was met 
by a gradual genetic modulation 
that enabled him to survive. The 
species has arrived at the current 
state of advanced physiologic capa-
bility-admirably adapted to its 
environment. We can dig diamonds 
at 9,000 feet in 123° heat and 
100% humidity; we can spend a 
lifetime mining tin at a 14,900-foot 
elevation, we can hike across the 
pole, and we can float weightless-
in-space for 14 days. 
But in the past few decades we 
have devised techniques unprece-
dented in the previous experience 
of the species to challenge the 
adaptability of the organism. We 
have designed molecules unique to 
human physiology and have in-
truded them into blood and tissue 
by techniques that are also unique 
in physiologic experience. Intraven-
ous, intramuscular and subcutan-
eous injections, positive pressure in-
halation, rectal administration, and 
agents that facilitate passage 
through intact skin all are unfamil-
iar modes of gaining access to the 
body. Add, for example, radiation 
by x-ray, beta ray, gamma ray and 
neutrons, plus oxygen under greatly 
increased barometric pressure, and 
one begins to appreciate the magni-
tude and genius of man's conspir-
acy to by-pass the conventional 
avenues for introducing new envir-
onmental factors to the physiology 
of man. 
In the past we only had to cope 
with nature and environment. And 
they were confined to the gastro-
intestinal tract, lungs and occasion-
ally the abraided skin to admit 
alien materials to the core of man. 
The implications of these ingen-
ious tactics of assault, these strange 
man-made chemicals and emana-
tions upon the beleaguered human 
mechanism are fascinating to con-
template. One could speculate that 
this incredibly resilient physiologic 
machine of ours is sufficiently ad-
vanced in design to be able to cope 
with all transgressors. We have 
evolved defenses at all levels from 
the simplest reflex to the most com-
plex immune reactions to meet the 
daily challenges of environment. 
And we have done very well in the 
matter of self preservation. 
Yet it is quite evident that some 
of these unprecedented therapeutic 
intrusions will overtax the ability 
of the body to accommodate, and it 
will react with displeasure, if not 
violent rejection. Of course this is 
the heart of our thesis, drug-in-
duced diseases. 
Every new drug must be eval-
uated for efficacy and toxicity, and 
this is not an easy task. Only pas-
sage of time and acquisition of ex-
perience will determine the ultimate 
verdict. Firm pronouncements 
based on animal experimentation or 
fragmentary early clinical trials are 
premature and meaningless. Often 
it takes years before the full spec-
trum of efficacy or toxicity of a 
drug becomes evident. This poses 
an almost insoluble conundrum. If 
we are timid and withhold the drug, 
how will we ever gain the necessary 
clinical experience? If the agent is 
effective and safe, it would seem 
unfair to withhold it. But if the 
drug is ineffective or toxic, it would 
seem equally unfair to use it on pa-
tients. All that one can propose is 
prudence, caution, and reservation 
of final judgment until objective 
studies are completed. 
In an effort to dramatize the 
problem of drug toxicity, I have 
selected one group of drugs, the 
tetracyclines, to serve as a proto-
type to illustrate the continuing 
challenge that faces the medical 
profession in arriving at a compre-
hensive appreciation of the spec-
trum of toxic effects of drugs. One 
might select almost any popular 
drug to do the same thing. This 
could properly be called the evolu-
tion of the toxic profile of a drug. 
Tetracyclines are valuable thera-
peutic allies. They qualify as anti-
biotics of choice in a host of in-
fectious diseases. So let it be 
established at the outset, there is no 
denying the efficacy of tetracyclines 
in clinical medicine. 
Included in this group of drugs 
are chlortetracycline (Aureomycin) 
oxytetracycline (Terramycin), te-
tracycline, tetracycline phosphate 
and rolitetracycline. 
Chlortetracycline was introduced 
in 1947. Despite the wearisome 
flurry of superlatives that attends 
the introduction of every major 
new drug, chlortetracycline was 
found to be remarkably effective. 
By 1949, a reflective review of the 
literature on this drug stated "it 
is an important landmark in the 
field of antibiotics. Its extremely 
low toxicity and wide range of ac-
tivity and absorbability from the 
gastrointestinal tract combine to 
make it a powerful therapeutic 
weapon" (Rose and Kneeland, 
1949). A prodigious literature ex-
tolling its virtues soon accumu-
lated. 
Early adverse effects were minor. 
They could almost be characterized 
as annoyances, and they were con-
fined to the gastrointestinal tract. 
Loss of appetite, nausea, vomiting, 
flatulence, dyspepsia and diarrhea 
occurred in about 10% of patients 
receiving significant doses (Pflug, 
1963; Schindel, 1965; Bevelander, 
1963). For several years the pro-
fession was quietly congratulating 
itself on having found a new variety 
of wonder drug with broad ap-
plication and low toxicity. Even the 
appellation "broad spectrum antibi-
otic" had a solid ring, adding a di-
mension of comprehensive cover-
age and confidence. 
In the early 1950's slight rumb-
lings could be heard in this thera-
peutic paradise. Other adverse ef-
fects related to gastrointestinal tract, 
more severe than the early ones, 
began to creep into clinical cog-
nizance. 
Antibiotics, especially the tetra-
cyclines, can disrupt the normal 
ecologic balance of the colon. De-
struction of friendly commensals 
facilitates overgrowth of organisms 
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resistant to the antibiotic. And, of 
course, if any of these hostile bac-
teria escape their enteric confines 
and gain access to blood or urinary 
tract, they can cause significant mis-
chief. 
This alteration of bacterial flora 
has been associated with stomatitis, 
glossitis, pharyngitis, and black 
hairy tongue, a cosmetically gro-
tesque, but pathologically benign 
condition. Also xerostomia, hoarse-
ness, and vulvo-vaginitis were re-
lated to tetracycline treatment. In 
most of these situations, disruption 
of bacterial balance permitted the 
fungus Monilia Albicans to flourish 
in these unseemly sites (Pflug, 
1963 ; Bonniot, 1964; Caruso, 1961; 
Clendenning, 1965). 
A corollary phenomenon was the 
rare occurrence of bleeding in eld-
erly patients with cirrhosis of the 
liver. It was postulated that the 
damaged liver was less efficient in 
producing its coagulation factors. 
Added to this was the belief that 
Vitamin K synthesis in the small 
bowel was inhibited by the altera-
tion of flora incident to tetracycline 
administration. But now this mech-
anism is strongly disputed. A final 
step in this hypothetical pathogen-
esis was that the sick liver, already 
struggling to produce its coagula-
tion factors, had its supply of Vita-
min K cut off. Therefore, no Vita-
min K, no coagulation factor-and 
we have bleeding. Unfortunately, 
there is little evidence to support 
this concept. 
It was in 1958 that from the 
British Isles, Germany, and Scanda-
navia came word that an old scourge 
was revisiting us with a vengeance. 
This was the granddaddy of all 
gastrointestinal syndromes that tet-
racyclines and other antibiotics had 
caused: staphylococcal pseudomem-
branous entercolitis (Bonniot, 
1964; Caruso, 1961; Clendenning, 
1965; Altemeier, Hummel, and 
Hill, 1963; Nemeth, Feher, and 
Szinay, 1963; Pockrandt, 1964; Si-
vertssen and Juel, 1958; Wegmann 
and Bucher, 1964). Once the 
friendly bacteria had been deci-
mated by the antibiotic, the Staphy-
lococcus, previously suppressed by 
normal bacterial inhabitants, had 
gained ascendency and invaded the 
colon wall. This resulted in de-
struction of the superficial cellular 
layers, with necrosis and sloughing. 
The result was a denuded colon 
wall which wept vast amounts of 
fluid, and death was not an infre-
quent consequence. 
This dread complication had 
been known before antibiotics, but 
there was a distinct impression that 
the incidence had risen significantly 
with the use of antibiotics, includ-
ing the tetracyclines. It was a tragic 
paradox that in some instances the 
antibiotics had been given in a sin-
cere but naive effort to prevent the 
development of a bacterial infec-
tion. 
In the early 1960's, rare sporadic 
cases were recorded describing a 
variety of hypersensitivity reactions. 
These included sudden cardiovascu-
lar collapse due to anaphylaxis, 
(Bedford, 1951 ; Editorial, J.A.M. 
A., 1965; Fellner and Baer, 1965). 
Others included ecchymoses (Scho-
enfeld, 1964) , hemolytic anemia 
(Takahashi, 1963), and dermato-
logic reactions (Schindel, 1965). 
A related and even more cur-
ious problem was the reactivation 
of systematic lupus erythematosus 
(Domz et al., 1959). Some observ-
ers even reported the precipitation 
of this disease de novo, following 
the administration of tetracyclines 
(Sulkowski and Haserick, 1964) . 
This must be an unusual occur-
rence, since I have seen no subse-
quent reports. 
In early 1963, a paper appeared 
which described a new entity re-
lated to tetracyclines. It bore super-
ficial resemblance to diabetes melli-
tus, since there was an excess of 
glucose in the urine and even al-
bumin. But closer scrutiny revealed 
that amino-acids also were being 
excreted. Thus it conformed to the 
pattern that had only been ohserved 
previously in patients with the Fan-
coni syndrome (Cleveland et al., 
1965; Castell and Sparks, 1965; 
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Editorial, Medicina, 1965; Frimp-
ter, Timpanelli; and Eisenmenger, 
1963; Fulop and Drapkin, 1965; 
Gross, 1963; Rice, Anderson, and 
Clark, 1964). 
It was an intriguing situation, 
especially when the cases were col-
lated and it was discovered that all 
victims had ingested out-dated tet-
racycline. The mysterious malady 
regressed about one month after 
the drug had been withdrawn. 
Warnings went out to physicians 
and pharmacists advising them to 
prescribe precise amounts of tetra-
cycline and to admonish thrifty pa-
tients to clean out the medicine 
chest. The American tradition of 
family sharing of unused antibiotics 
was publicly denounced. 
A paucity of subsequent reports 
seemed to indicate that the pharma-
ceutical industry had modified the 
procedure by deleting citrate to ob-
viate the problem of tetracycline 
degradation. However, two recent 
cases were reported in which potas-
sium depletion was a remarkable 
feature of a Fanconi Syndrome, 
again induced by out-dated tetra-
cycline. 
This incident called to mind 
some earlier work linking tetracy-
cline toxicity and renal disease (Ed-
itorial, Ann. Int. Med., 1963; Mav-
romatis, 1965; Pulliam and O'Leary, 
1964; Robins, 1963; Shils, 1963; 
Solomon, Galloway, and Patterson, 
1965; Wegienka and Weller, 1964; 
Zimmerman and Werther, 1964). 
These antibiotics tend to interfere 
with protein synthesis. In patients 
with poor kidney function, tetra-
cyclines may exaggerate elevation 
of blood urea nitrogen. Rarely, an 
excessive sodium diuresis may 
cause hyponatremia. As the kidney 
disease becomes more severe and 
function declines, the tetracycline-
induced problems are compounded 
proportionately. Severe retention of 
protein breakdown products, urea 
and phosphate, resu1t in a metabolic 
acidosis, and this· could cause loss 
of weight, uremic symptoms, in-
cluding anorexia, nausea and vomit-
ing. Tetracycline adminstration to 
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the unfortunate patient with severe 
renal disease may result in exacer-
bation of clinical uremia; gastric 
ulceration and bleeding has been 
reported. 
In 1963 a new dimension was 
added to the tetracycline story. It 
was discovered that these drugs had 
a strange affinity for teeth, bones 
and tumors (Benson, 1964; Cuttita, 
1965; Editorial, J. Am. Dental 
Assoc., 1964; Editorial, Lancet, 
1965; Editorial, Nutrition R ev., 
1964; Frankel and Hawes, 1964; 
Hilton, 1962; Kutscher, et al., 
1963; Kvaal, 1965; Madison, 1963; 
Stewart, 1964; Swallow, 1964; Ta-
guchi, 1963; Vickers, 1964; Wall-
man and Hilton, 1962; Weyman, 
1965; Witkop and Wolf, 1963) . A 
group of 50 young children were 
receiving long-term chlortetracy-
cline or oxytetracycline for the con-
trol of pulmonary infection associ-
ated with cystic fibrosis. Staining 
of the teeth occurred in 80%. 
Those given tetracyclines in early 
infancy exhibited the most ·severe 
discolorations. 
Apparently tetracycline has an 
affinity for the active growth sites 
of bones and teeth; it migrates to 
these areas soon after it is given, 
and there it remains. A definite in-
hibition of normal calcification oc-
curs at these sites of tetracycline 
deposition. 
In teeth this amounts to delayed 
growth and intrinsic staining of 
dental enamel; this may be the 
commonest cause of deciduous 
enamel discoloration in infants. 
Perhaps equally distressing is the 
capability of tetracyclines to mi-
grate through the maternal placenta 
to be deposited in the skeleton of 
the fetus (Tubaro, 1964). In pre-
mature infants this could cause in-
hibition of bone growth. On a hap-
pier note, it must be noted that this 
effect is reversible if the course of 
tetracyclines given to the mother is 
brief. 
Other authors have suggested 
that tetracyclines administered to 
women in early pregnancy could 
result in congenital abnormalities·in 
their off-spring (Barkalaia, 1964; 
Manning, 1964; Cobian, Bevelan-
der, and Tiamsic, 1963) . The data 
here was entirely inferential. This 
did call to mind a paper published 
in 1963, which described a strange 
phenomenon in which tetracyclines 
administered to six infants caused 
a rise in cerebro-spinal fluid pres-
sure with bulging of the fontanelle. 
This process regressed promptly 
upon withdrawal of the drug (Op-
fer, 1963). This is most assuredly 
a rare adverse effect. I have seen 
no subsequent reports of this phe-
nomenon. 
In another direction it has been 
observed that some individuals who 
are taking tetracyclines develop in-
creased sensitivity to sunlight (de-
Veber, 1962; Kingsley, 1963; Sas-
low, 1961; Soga!, 1963; Storck, 
1965; Tromovich and Jacobs, 
1963). This apparently is more se-
vere with demethylchlortetracycline, 
but has occurred with others of the 
group. This may take a rather 
severe form on rare occasions with 
actual epidermolysis. 
Later a report described a young 
lady who became myopic while 
taking tetracycline; it disappeared 
when she stopped the drug (Cap-
perucci, 1964; Edwards, 1963). 
Later a few others made similar 
observations. 
In 1964, Dr. Searcy and co-
workers reported that tetracycline 
when given intravenously interfered 
with coagulation of blood (Searcy, 
Simms, and Foremar, 1964; Searcy 
et al., 1965). This was considered 
to be a direct effect against specific 
clotting factors. These patients did 
not have liver disease and there 
was no apparent disturbance of 
Vitamin K production. 
In late 1963, the New England 
Journal of Medicine carried an ar-
ticle that described the deadly mis-
fortunes of six young pregnant 
women who developed kidney in-
fections. They were given tetracy-
cline intravenously in larger than 
average doses by the intravenous 
route. All died within 5 to 13 days 
after the start of tetracycline treat-
ment. Examination at post mortem 
revealed identical changes in their 
livers (Schultz et al., 1963) . Sev-
eral more cases were reported sub-
sequently (Brewer, 1965; Cairella, 
Trasatti, and Becchi, 1964; Editor-
ial, Brit. Med. J., 1964; Finn and 
Horwitz, 1965; Horwitz and Mary-
mont, 1964; Kunelis, Peters, and 
Edmondson, 1965; Norman, 
Schultz, and Hoke, 1964; Orentre-
ich and Berger, 1965; Popper et al., 
1965: Wruble et al., 1965; Wruble 
and Cummins, 1965). 
This episode was climaxed by a 
formal statement by the American 
Medical Association, Council on 
Drugs. "Tetracycline given intra-
venously should be prescribed with 
caution in women in the last tri-
mester of pregnancy. When admin-
istered, its concentration in serum 
should be controlled and liver func-
tion tests should be made at fre-
quent intervals. Finally, it is im-
portant that physicians refrain from 
prescribing other potentially hepa-
totoxic drugs concomitantly" (Dow-
ling and Lepper, 1964) . 
This appeared on April 20, 1964. 
It was a conservative statement at 
the time. Today we have other 
drugs with the same area of effec-
tiveness as tetracyclines, but with 
no known toxic effect upon the 
liver. 
And all of this is not over. Just 
a few months ago an article ap-
peared describing thrombocytopenia 
related. to tetracyclines (FDA Re-
ports, 1966). And this was almost 
20 years after the first clinical ex-
perience with this group of drugs. 
Again I wish to emphasize that 
tetracyclines are valuable antibiot-
ics. I prescribe them; all of us do, 
but they are not entirely benign 
(Moser, 1966). And it has taken 
almost 20 years to appreciate this. 
One may ask, how can it be that 
it takes so lon{?? The answer is 
not easy. I can cite my own experi-
ence .with another drug. Soon after 
it appeared on the market, I pre-
scribed Serpasil for a patient. Soon 
she complained of paresthesias and 
tremors. 
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I searched the literature; there 
was nothing. I considered this a 
neurotic manifestation, patted my 
patient on the head, and persisted 
in my naivete and ignorance. Fi-
nally symptoms became more se-
vere; I stopped the drug; symptoms 
regressed. I started the drug again; 
symptoms recurred. At least I was 
convinced. The patient (who hap-
pened to be my wife) was also con-
vinced that I was an idiot. And 
one week later the first article ap-
peared on Serpasil-induced tremors. 
This is not an uncommon experi-
ence, and that is why it often takes 
20 years. 
Conclusion 
"Diseases of Medical Progress" 
will be with us forevermore. They 
cannot be swept under the rug, 
either by clinician or drug pro-
ducer. My own naivete in the world 
of commerical enterprise is revealed 
by my admission that I think a fine 
new drug will become known to the 
profession on the basis of its merit. 
I am embarrassed when this noble 
community is demeaned by mer-
chandizing techniques, however 
subtle or artful, better suited to less 
vital products, such as soap or soda 
pop. The fact that over . $750 mil-
lion is spent each year for drug ad-
vertising is a staggering testimonial 
to the enormity of this effort. This 
is almost three times more money 
than is required to run all of the 
medical schools in this country for 
one year. I do not feel that drugs 
should be propagandized to the 
medical profession. The pressure of 
commercial competition is not con-
ducive to objectivity in the presen-
tations ' of drug detail men or in 
published advertisements. ·I · feel 
these factors add to the confusion 
in the already . difficult prob0lems of 
evaluating the efficacy or adverse 
effects of new drugs. 
The requirement for a'n impartial 
agency that can provide current, 
reliable and objective data ·about 
the characteristics of riew drugs, 
and alert the physieiari to their 
toxic hazards is abundantly evi-
dent. This requirement has been 
met by the American Medical As-
sociation Council on Drugs, which 
created a national "Registry of Ad-
verse Reactions." A comparatively 
new facility, it was the natural suc-
cessor to the "Registry of Drug-
Induced Blood Dyscrasias," a most 
successful pioneer study guided and 
nurtured by Dr. Maxwell M. Win-
trobe and Dr. Charles Huguley. 
The new, broader registry makes it 
possible for any physician to con-
tribute his personal experience with 
adverse drug effects to a central 
pool. This information is recorded 
on a form designed for automatic 
data processing. The data are ex-
tracted and recorded in the memory 
banks of a computer system. 
Volunteer teams of nationally 
recognized specialists study all in-
formation submitted to the Reg-
istry. Thus, the input from physi-
cians throughout the country is 
evaluated and recorded . Hopefully, 
for the first time, we have the 
means to obtain realistic incidence 
data about adverse drug effects. 
The response from hospitals and 
private physicians has been disap-
pointing, in quantity and quality 
but the program is young, and al-
ready the Journal of the American 
Medical Association has carried 
several brief pertinent articles de-
scribing recently discovered adverse 
drug effects and summarizing drug 
information derived from this new 
facility. 
The Federal Drug Administra-
tion has inaugurated a similar pro-
gram that complements the AMA 
Registry and expands the total data 
gathering capability. FDA concern 
in the matter is oriented somewhat 
differently from that of the AMA. 
Nevertheless, such activity in the 
nation's highest medical councils 
indicates the growing importance 
of adverse drug effects. 
The AMA Registry represented a 
significant step toward meeting the 
challenge of new responsibility that 
accompanies increased capability. 




is a tribute to the commercial drug 
industry and the devoted chemists 
and pharmacologists of our medical 
schools. But neither medical 
schools, AMA, FDA, nor the industry 
can solve the problem completely. 
My plea has been, and is directed 
to the physician on the firing line, 
the doctor who prescribes the drug. 
It is farthest from my intention to 
suggest therapeutic timidity or ho-
meopathy. Our predecessors in 
medicine had limited diagnostic and 
therapeutic resources. The comple-
ment of nostrums in their little 
black bag was austere, but these 
drugs were regarded as old familiar 
friends. Some were worthless, oth-
ers dangerous; some were impure 
and unstandardized to the point of 
unpredictability. The few effective 
drugs were trusted allies whose 
strengths and weaknesses were well 
known. The practitioner of the past 
attempted to compensate for lack 
of material resources with meticu-
lous attention to his patients, per-
sonal charm, kindness, and pervad-
ing equanimity. 
His lonely hours of private hell, 
tormented by his inability to come 
to grips with most of the severe ill-
nesses that he encountered, con-
stitute a long, bleak chapter in 
medical history . The modern phy-
sician is afforded rare glimpses of 
this agony when faced with ma-
lignancy or degenerative disease or 
neurologic illness. Modern phar-
macology has brought this un-
happy era to an end; we now enjoy 
the privilege of fine, powerful, 
well-standardi zed therapeutic 
weapons. 
Now we must work to create an 
atmosphere of rational caution and 
critical evaluation, where each 
physician will pause before putting 
pen to prescription pad and ask 
himself, "Do I know enough 
about this drug to prescribe it? 
Does the possible benefit I hope 
to derive from this drug outweigh 
its potential hazard?" I do not 
preach therapeutic nihilism, but 
rather therapeutic rationalism. 
Thank you. 
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